HIV Vaccine Trial Results — An Opening for Further Research

HIV-AIDS has emerged as an enormous, worldwide public health problem over the past 25 years. An estimated 33 million persons are infected with human immunodeficiency virus type 1 (HIV-1), and more than 7000 new infections occur every day.1 Although major advances have been made in the treatment of HIV-1 infection and in certain behavioral approaches to the prevention of HIV infection, ultimately, control will most likely depend on the development and application of a safe and effective HIV vaccine. Substantial effort is being expended to develop an HIV vaccine through a variety of approaches.2 However, disappointing results have emerged from . . .